Want to join the conversation?
As a result of its 1Q16 results and the recent acquisition of Zee Medical, $CTAS updated its annual guidance and now expects FY16 revenue to be in the range of $4.80-4.88Bil & EPS from continuing operations to be in the range of $3.79-3.88. This guidance does not include any potential deterioration in the U.S. economy or additional share buybacks.
$TWTR mentions Snap as one of its fiercest rivals in its 10K filing. Great head start for Snap ahead of IPO!